Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomised, Single Center, 2 Way Crossover Study to Assess Bioequivalence Between a Commercial HPMC Capsule of D961H 20 mg and a Pellets Based Sachet Formulation of D961H 20 mg by Pharmacodynamics (Intragastric pH) After Once-daily Repeated Oral Administration in Japanese Healthy Male Subjects

NCT01964131 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01964131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01964131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomised, Single Center, 2 Way Crossover Study to Assess Bioequivalence Between a Commercial HPMC Capsule of D961H 20 mg and a Pellets Based Sachet Formulation of D961H 20 mg by Pharmacodynamics (Intragastric pH) After Once-daily Repeated Oral Administration in Japanese Healthy Male Subjects
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2013
Completion date
December 31, 2013
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anastomotic ulcer, duodenal ulcer, etc., gastric ulcer, reflux esophagitis